Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Risk for further dilution?

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Jul 07, 2022 10:16am

174 Views

Post# 34808119

RE:RE:RE:Risk for further dilution?

yes, I agree with these points but it is possible at this point that the share price will not reach 0.60 and these outstanding warrants can be the equivalent offset in number of shares re: dilution

I think that the plan is to continue developing the company with the forthcoming manoeuvres, the price will go up through the $1 ceiling and then nobody here will care if 5,10 or 20 million shares are issued to support institutional participation and uplisting.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China